Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Dare Bioscience (DARE) over the last 11 years, with Q2 2025 value amounting to $448000.0.

  • Dare Bioscience's Gains from Investment Securities changed N/A to $448000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 39335.82%. This contributed to the annual value of -$600000.0 for FY2024, which is 14646.03% down from last year.
  • Latest data reveals that Dare Bioscience reported Gains from Investment Securities of $448000.0 as of Q2 2025.
  • Dare Bioscience's Gains from Investment Securities' 5-year high stood at $2.8 million during Q1 2025, with a 5-year trough of -$600000.0 in Q1 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was $237539.0 (2021), whereas its average is $487492.7.
  • Per our database at Business Quant, Dare Bioscience's Gains from Investment Securities tumbled by 46026.3% in 2024 and then skyrocketed by 57350.45% in 2025.
  • Over the past 5 years, Dare Bioscience's Gains from Investment Securities (Quarter) stood at $308533.0 in 2021, then crashed by 248.33% to -$457648.0 in 2022, then soared by 376.78% to $1.3 million in 2023, then crashed by 147.37% to -$600000.0 in 2024, then skyrocketed by 174.67% to $448000.0 in 2025.
  • Its last three reported values are $448000.0 in Q2 2025, $2.8 million for Q1 2025, and -$600000.0 during Q1 2024.